McGill University

Academic Institute

Samy Suissa - Chief Investigator - McGill UniversitySamy Suissa - Corresponding Applicant - McGill UniversityMichael Wallace - Collaborator - University Of WaterlooPierre Ernst - Collaborator - McGill UniversitySophie Dell'Aniello - Collaborator - McGill University

CPRD12

Chronic obstructive pulmonary disease (COPD) is now the third leading cause of death worldwide. Pharmacological treatments for COPD include long-acting bronchodilators and inhaled corticosteroids. These latter medications are associated with some known risks, including pneumonia, while their effectiveness may vary with different patient characteristics, including certain blood markers, asthma, frequent exacerbations and smoking patterns.

Chronic obstructive pulmonary disease (COPD) has become the third leading cause of death worldwide. Long-acting beta2-agonists (LABAs), long-acting muscarinic antagonists (LAMAs) and inhaled corticosteroids (ICS) are central pharmacologic therapies for COPD. ICS are associated with some known risks, including pneumonia, while their effectiveness appears to vary with different patient characteristics, including blood eosinophil counts, asthma, frequent exacerbations and smoking. We propose to determine the optimal initial and subsequent treatment strategy for COPD, balancing effectiveness and risk, according to specific patient characteristics.

11/06/2021

Release